Opthea's Wet AMD Program Featured at FLORetina 2024
Ticker: OPTEY · Form: 6-K · Filed: Nov 26, 2024 · CIK: 1815620
Sentiment: neutral
Topics: clinical-trial-data, conference-presentation, ophthalmology, biotech
TL;DR
Opthea presenting wet AMD data at FLORetina 2024 - could be big for their drug.
AI Summary
Opthea Ltd. announced on November 26, 2024, that its wet AMD program will be presented at the FLORetina 2024 conference. The presentation will feature data from Opthea's Phase 3 clinical trials for its novel therapy targeting wet age-related macular degeneration.
Why It Matters
This presentation at a key ophthalmology conference could highlight the potential of Opthea's therapy for a significant unmet medical need, potentially impacting future treatment paradigms for wet AMD.
Risk Assessment
Risk Level: medium — The company is presenting clinical trial data, which is a crucial step, but the ultimate success and market adoption of their therapy are still subject to regulatory approval and further clinical outcomes.
Key Players & Entities
- Opthea Ltd. (company) — Registrant
- FLORetina 2024 (event) — Conference where data will be presented
- November 26, 2024 (date) — Date of the filing
- 001-39621 (other) — SEC File Number
FAQ
What specific data from Opthea's wet AMD program will be presented at FLORetina 2024?
The filing states that Opthea's wet AMD program will be featured, and Exhibit 99.1 is a press release detailing this, but the specific data points are not included in this 6-K form itself.
When is FLORetina 2024 taking place?
The filing does not specify the exact dates of the FLORetina 2024 conference, only that Opthea's program will be featured during the month of November 2024.
What is the primary focus of Opthea's wet AMD program?
Opthea's program is focused on developing a novel therapy for wet age-related macular degeneration (AMD).
Does this filing include financial information for Opthea Ltd.?
No, this is a Form 6-K, which typically reports on material events or information that a foreign private issuer makes public in its home country. This specific filing focuses on the presentation of clinical data.
What is the SIC code for Opthea Ltd.?
The Standard Industrial Classification (SIC) code for Opthea Ltd. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 152 words · 1 min read · ~1 pages · Grade level 13.2 · Accepted 2024-11-26 06:02:23
Filing Documents
- opt_-_opthea_floretina.htm (6-K) — 24KB
- opt-ex99_1.htm (EX-99.1) — 21KB
- img260626642_0.jpg (GRAPHIC) — 61KB
- img260626642_1.jpg (GRAPHIC) — 61KB
- 0000950170-24-130745.txt ( ) — 214KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized. OPTHEA LIMITED (Registrant) By: /s/ Frederic Guerard Name: Frederic Guerard Title: Chief Executive Officer Date: 11/26/2024